免疫腫瘤學市場：按治療類型、疾病類型、分銷渠道、地區劃分——規模、份額、展望、機會分析，2022-2030 年

免疫腫瘤學是研究和開發利用人體免疫系統對抗癌症的療法。 免疫系統是一個由器官、細胞和分子組成的複雜網絡，可以保護身體免受引起感染的外來物質的侵害。 除了發現和消滅外來物質，免疫系統還能發現和攻擊異常細胞。 免疫腫瘤學使用新的免疫療法來增強患者的免疫系統。 這些治療針對身體的免疫系統而不是腫瘤，從而使免疫系統能夠識別和靶向癌細胞。 與化學療法和放射療法等傳統療法不同，免疫腫瘤學不會影響健康細胞的功能。 這些治療讓您的免疫系統擁有長期記憶，因此您可以獲得持久的反應。 隨著時間的推移，免疫系統會適應癌症，並對癌症產生持久的反應。 免疫腫瘤學療法可有效治療多種癌症類型，包括非小細胞肺癌、急性髓性白血病、淋巴瘤、多發性骨髓瘤和乳腺癌。

市場動態

預測期內，主要市場參與者的產品批准等無機策略的增加預計將推動全球免疫腫瘤藥物市場。 例如，2020 年 12 月，生物技術公司 Blueprint Medicines Corporation 獲得美國食品藥品監督管理局批准 GAVRETO（prarcetinib）用於治療晚期或轉移性 RET 突變和 RET 融合陽性甲狀腺癌患者，宣布獲批。 GAVRETO 是一種每日一次的口服精準治療藥物，旨在有效和選擇性地靶向驅動多種腫瘤類型的 RET 改變。

這項研究的主要特點

• 本報告對全球免疫腫瘤藥物市場進行了深入分析，顯示了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。I在這裡。
• 它揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資建議矩陣。
• 它還提供了有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭戰略等方面的重要見解。
• 根據公司亮點、產品組合、主要亮點、績效和戰略等參數對全球免疫腫瘤學市場的主要參與者進行了概況分析。
• 本研究涵蓋的主要公司包括 AbbVie Inc.、AstraZeneca、Bristol-Myers Squibb Company、Dendreon Pharmaceuticals LLC.、F. Hoffmann-La Roche Ltd.、Merck & Co., Inc.、Novartis AG、Pfizer Inc.、Sanofi、Ferring B.V.、Enzo Biochem Inc.、Celldex Therapeutics、Atara Biotherapeutics, Inc.、Apexigen、BioNTech SE、Blueprint Medicines Corporation、Regeneron Pharmaceuticals Inc.、CytomX Therapeutics, Inc.、Agenus Inc.、Betta Pharmaceuticals Co. , Ltd.、CStone Pharmaceuticals、Amgen Inc.、MediMergent, LLC、Gilead Sciences, Inc. 和 ONKO-INNATE
• 這份報告中的見解將使企業營銷人員和高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
• 《全球免疫腫瘤學市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者將能夠通過用於分析全球免疫腫瘤學市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第2章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按治療類型分類
  • 按疾病類型劃分的市場概況
  • 市場概況：按銷售渠道
  • 市場概況：按地區
• 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 市場機會
• 影響分析
• 市場趨勢
• 管道分析
• 收購和合作場景
• 監管場景
• 主要發展狀況
• COVID-19 影響分析

第 4 章免疫腫瘤藥物的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 總體影響
• 政府舉措
• COVID-19 對市場的影響

第 5 章全球免疫腫瘤學市場，按治療類型，2017-2030

• 免疫檢查點抑製劑
• PD-1
• PD-L1
• CTLA-4
• 免疫系統調節劑
• 癌症疫苗
• 腫瘤治療病毒
• 其他

第 6 章全球免疫腫瘤藥物市場，按疾病類型，2017-2030

• 黑色素瘤
• 肺癌
• 血癌
• 腎細胞癌
• 前列腺癌
• 膀胱癌
• 其他（乳腺癌、甲狀腺癌等）

第 7 章全球免疫腫瘤市場，按分銷渠道，2017-2030

• 醫院藥房
• 零售藥房
• 在線藥店

第 8 章全球免疫腫瘤學市場，按地區劃分，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第9章競爭格局

• AbbVie Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• Dendreon Pharmaceuticals LLC.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Ferring B.V.
• Enzo Biochem Inc.
• Celldex Therapeutics
• Atara Biotherapeutics, Inc.
• Apexigen
• BioNTech SE
• Blueprint Medicines Corporation
• Regeneron Pharmaceuticals Inc.
• CytomX Therapeutics, Inc.
• Agenus Inc.
• Betta Pharmaceuticals Co., Ltd.
• CStone Pharmaceuticals
• Amgen Inc.
• MediMergent, LLC
• Gilead Sciences, Inc.
• ONKO-INNATE

第10章 章節

• 調查手法
• 關於出版社

Immuno-oncology is the study and development of treatments that take advantage of the body's immune system to fight cancer. As immune system is a complex network of organs, cells and molecules that protect the body from foreign substances that cause infection. In addition to finding and destroying foreign substances, the immune system can also locate and attack abnormal cells. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.

Market Dynamics

Increasing number of inorganic strategies such as product approval by the key market players is expected to drive the global immuno-oncology drugs market over the forecast period. For instance, in December 2020, Blueprint Medicines Corporation, a biotech company, announced that they had received an approval from the U.S. Food and Drugs Administration for GAVRETO (pralsetinib) for the treatment of patients with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancer. GAVRETO is a once-daily oral precision therapy designed to potently and selectively target RET alterations that drive multiple tumor types.

Key features of the study:

• This report provides an in-depth analysis of the global immuno-oncology drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global immuno-oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation:

• Global Immuno-oncology Drugs Market, By Treatment Type:
  • Immune Checkpoint Inhibitors
    • PD-1
    • PD-L1
    • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others
• Global Immuno-oncology Drugs Market, By Disease Type:
  • Melanoma
  • Lung Cancer
  • Blood Cancer
  • Renal Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer
  • Others (Breast Cancer, Thyroid Cancer, etc.)
• Global Immuno-oncology Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Immuno-oncology Drugs Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AbbVie Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Dendreon Pharmaceuticals LLC.
  • Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Ferring B.V.
  • Enzo Biochem Inc.
  • Celldex Therapeutics
  • Atara Biotherapeutics, Inc.
  • Apexigen
  • BioNTech SE
  • Blueprint Medicines Corporation
  • Regeneron Pharmaceuticals Inc.
  • CytomX Therapeutics, Inc.
  • Agenus Inc.
  • Betta Pharmaceuticals Co., Ltd.
  • CStone Pharmaceuticals
  • Amgen Inc.
  • MediMergent, LLC,
  • Gilead Sciences, Inc.
  • ONKO-INNATE

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Pipeline Analysis
• Acquisitions and Partnerships Scenario
• Regulatory Scenario
• Key Developments
• COVID-19 Impact Analysis

4. Global Immuno-oncology Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Immuno-oncology Drugs Market, By Treatment Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Immune Checkpoint Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• PD-1
• PD-L1
• CTLA-4
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Cancer Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Oncolytic Virus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Immuno-oncology Drugs Market, By Disease Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Melanoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Blood Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Renal Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (Breast Cancer, Thyroid Cancer, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Immuno-oncology Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Immuno-oncology Drugs Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2017 - Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
• Bristol-Myers Squibb Company
• Dendreon Pharmaceuticals LLC.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Ferring B.V.
• Enzo Biochem Inc.
• Celldex Therapeutics
• Atara Biotherapeutics, Inc.
• Apexigen
• BioNTech SE
• Blueprint Medicines Corporation
• Regeneron Pharmaceuticals Inc.
• CytomX Therapeutics, Inc.
• Agenus Inc.
• Betta Pharmaceuticals Co., Ltd.
• CStone Pharmaceuticals
• Amgen Inc.
• MediMergent, LLC
• Gilead Sciences, Inc.
• ONKO-INNATE

10. Section

• Research Methodology
• About Us